|
[1]KOJIMA S, WATANABE N.Current status of portal vein thrombosis in Japan:Results of a questionnaire survey by the Japan Society for Portal Hypertension[J].Hepatol Res, 2018, 48 (4) :244-254.
|
|
[2] CHAWLA Y, DUSEJA A, DHIMAN RK.Review article:The modern management of portal vein thrombosis[J].Aliment Pharmacol Ther, 2009, 30 (9) :881-894.
|
|
[3] HALL TC, GARCEA G, METCALFE M, et al.Management of acute non-cirrhotic and non-malignant portal vein thrombosis:Asystematic review[J].World J Surg, 2011, 35 (11) :2510-2520.
|
|
[4]DAVIES M, SATYADAS T, AKLE CA.Spontaneous resolution of a superior mesenteric vein thrombosis after laparoscopic nissen fundoplication[J].Ann R Coll Surg Engl, 2002, 84 (3) :177-180.
|
|
[5]LOFFREDO L, PASTORI D, FARCOMENI A, et al.Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:Asystematic review and meta-analysis[J].Gastroenterology, 2017, 153 (2) :480-487.e481.
|
|
[6]AGENO W, GALLI M, SQUIZZATO A, et al.Is there a role for timely diagnosis and early anticoagulant treatment of portal vein thrombosis in patients with liver cirrhosis?[J].Intern Emerg Med, 2008, 3 (3) :195-196.
|
|
[7]PONZIANI FR, ZOCCO MA, TORTORA A, et al.Anticoagulants in cirrhotic patients:Controversies and certainties in PVT management[J].Cardiovasc Hematol Agents Med Chem, 2011, 9 (3) :183-189.
|
|
[8]KAWADA PS, BRUCE A, MASSICOTTE P, et al.Coagulopathy in children with liver disease[J].J Pediatr Gastroenterol Nutr, 2017, 65 (6) :603-607.
|
|
[9]AMITRANO L, GUARDASCIONE MA, MENCHISE A, et al.Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis[J].J Clin Gastroenterol, 2010, 44 (6) :448-451.
|
|
[10]SENZOLO MT, M SARTORI T, ROSSETTO V, et al.Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis[J].Liver Int, 2012, 32 (6) :919-927.
|
|
[11] VILLA E, CAMMA C, MARIETTA M, et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology, 2012, 143 (5) :1253-1260.e1254.
|
|
[12]DELGADO MG, SEIJO S, YEPES I, et al.Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :776-783.
|
|
[13]NORTHUP PG, SUNDARAM V, FALLON MB, et al.Hypercoagulation and thrombophilia in liver disease[J].J Thromb Haemost, 2008, 6 (1) :2-9.
|
|
[14]HAAS S.The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes[J].Semin Vasc Med, 2003, 3 (2) :139-146.
|
|
[15]HIRSH J, WARKENTIN TE, SHAUGHNESSY SG, et al.Heparin and low-molecular-weight heparin:Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety[J].Chest, 2001, 119 (1 Suppl) :64s-94s.
|
|
[16]BIANCHINI M, CAVANI G, BONACCORSO A, et al.Low molecular weight heparin does not increase bleeding and mortality postendoscopic variceal band ligation in cirrhotic patients[J].Liver Int, 2018, 38 (7) :1253-1262.
|
|
[17]KWON J, KOH Y, YU SJ, et al.Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis:Efficacy and the risk of hemorrhagic complications[J].Thromb Res, 2018, 163:71-76.
|
|
[18]YANG H, KIM SR, SONG MJ.Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban[J].Clin Mol Hepatol, 2016, 22 (4) :499-502.
|
|
[19]HUGENHOLTZ GC, NORTHUP PG, PORTE RJ, et al.Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?[J].Blood Rev, 2015, 29 (2) :127-136.
|
|
[20]CHEN H, LIU L, QI X, et al.Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis[J].Eur J Gastroenterol Hepatol, 2016, 28 (1) :82-89.
|
|
[21]HANAFY AS, ABD-ELSALAM S, DAWOUD MM.Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis[J].Vascul Pharmacol, 2018.[Epub ahead of print]
|
|
[22]PANNACH S, BABATZ J, BEYER-WESTENDORF J.Successful treatment of acute portal vein thrombosis with rivaroxaban[J].Thromb Haemost, 2013, 110 (4) :626.
|
|
[23]LENZ K, DIEPLINGER B, BUDER R, et al.Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban[J].Z Gastroenterol, 2014, 52 (10) :1175-1177.
|
|
[24]INTAGLIATA NM, HENRY ZH, MAITLAND H, et al.Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation[J].Dig Dis Sci, 2016, 61 (6) :1721-1727.
|
|
[25]DARIUSHNIA SR, HASKAL ZJ, MIDIA M, et al.Quality improvement guidelines for transjugular intrahepatic portosystemic shunts[J].J Vasc Interv Radiol, 2016, 27 (1) :1-7.
|
|
[26]KEARON C, AKI EA, ORNELAS J, et al.Antithrombotic therapy for VTE disease:CHEST guideline and expert panel report[J].Chest, 2016, 149 (2) :315-352.
|
|
[27]BASIT SA, STONE CD, GISH R.Portal vein thrombosis[J].Clin Liver Dis, 2015, 19 (1) :199-221.
|
|
[28]PLESSIER A, RAUTOU PE, VALLA DC.Management of hepatic vascular diseases[J].J Hepatol, 2012, 56 (Suppl 1) :s25-s38.
|
|
[29] HOEKSTRA J, JANSSEN HL.Vascular liver disorders (II) :portal vein thrombosis[J].Neth J Med, 2009, 67 (2) :46-53.
|
|
[30]TURNES J, GARCIA-PAGAN JC, GONZALEZ M, et al.Portal hypertension-related complications after acute portal vein thrombosis:Impact of early anticoagulation[J].Clin Gastroenterol Hepatol, 2008, 6 (12) :1412-1417.
|
|
[31]WEBSTER GJ, BURROUGHS AK, RIORDAN SM.Review article:portal vein thrombosis-new insights into aetiology and management[J].Aliment Pharmacol Ther, 2005, 21 (1) :1-9.
|
|
[32]OGREN M, BERGQVIST D, BJORCK M, et al.Portal vein thrombosis:Prevalence, patient characteristics and lifetime risk:A population study based on 23, 796 consecutive autopsies[J].World JGastroenterol, 2006, 12 (13) :2115-2119.
|
|
[33]DELEVE LD, VALLA DC, GARCIA-TSAO G, et al.Vascular disorders of the liver.[J].Hepatology, 2009, 49 (5) :1729-1764.
|
|
[34]VILLA E, CAMMC, MARIETTA M, et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology, 2012, 143 (5) :1253-1260.
|
|
[35]CUI SB, SHU RH, YAN SP, et al.Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J].Eur J Gastroenterol Hepatol, 2015, 27 (8) :914-919.
|
|
[36]RODRGUEZ-LEAL GA, MORN S, CORONA-CEDILLO R, et al.Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient[J].World J Hepatol, 2014, 6 (7) :532-537.
|
|
[37]LI MX, ZHANG XF, LIU ZW, et al.Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis[J].Hepatobiliary Pancreat Dis Int, 2013, 12 (5) :512-519.
|
|
[38]RODRIGUEZ-CASTRO KI, SIMIONI P, BURRA P, et al.Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis[J].Liver Int, 2012, 32 (10) :1465-1476.
|
|
[39]PELLICELLI AM, GUARASCIO P, D'AMBROSIO C, et al.186 portal vein thrombosis in cirrhotic patients:Safety and efficacy of low dosage of enoxaparin[J].J Hepatol, 2010, 52 (1) :s80.
|
|
[40]LISMAN T, KAMPHUISEN PW, NORTHUP PG, et al.Established and new-generation antithrombotic drugs in patients with cirrhosis-possibilities and caveats[J].J Hepatol, 2013, 59 (2) :358-366.
|
DownLoad: